(Q44849386)

6 December 2017

title

Patient preferences for psoriasis treatments: impact of treatment experience (English)

1 reference

6 December 2017

1 reference

M-L Schaarschmidt

1

1 reference

6 December 2017

N Umar

2

1 reference

6 December 2017

A Schmieder

3

1 reference

6 December 2017

D D Terris

4

1 reference

6 December 2017

M Goebeler

5

1 reference

6 December 2017

S Goerdt

6

1 reference

6 December 2017

W K Peitsch

7

1 reference

6 December 2017

publication date

6 January 2012

1 reference

Journal of the European Academy of Dermatology and Venereology

6 December 2017

published in

1 reference

6 December 2017

volume

27

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

187-198

1 reference

A clinician's paradigm in the treatment of psoriasis

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Objective assessment of compliance with psoriasis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Maximizing patient adherence for optimal outcomes in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Treatment of psoriasis with fumaric acid esters (Fumaderm).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Time needed for treatment is the major predictor of quality of life in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

What's wrong with Bonferroni adjustments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Multiple test procedures other than Bonferroni's deserve wider use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Balancing the Benefits and Risks of Drug Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Ordering effect and price sensitivity in discrete choice experiments: need we worry?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-3083.2011.04440.X

10.1111/J.1468-3083.2011.04440.X

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference